Generic Name: esketamine hydrochloride
Brand Name: TBC
Manufacturer: Janssen Inc.
Indications: Major depressive disorder (MDD), adults
Manufacturer Requested Reimbursement Criteria1: Esketamine hydrochloride is indicated for the treatment of Major Depressive Disorder in adults who have not responded adequately to at least two different antidepressants of adequate dose and duration in the current depressive episode.
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input posted||May 27, 2019|
|Patient group input closed||July 16, 2019|
- Patient input submission received from the Canadian Mental Health Association, National; Canadian Mental Health Association, Alberta Division; Mood Disorders Association of Ontario and the Mood Disorders Society of Canada
|Patient input summary sent for review to patient input groups||-|
|Patient group comments on input summary closed||-|
|Submission received||June 24, 2019|
|Submission accepted for review||July 09, 2019|
|Review initiated||July 10, 2019|
|Draft CADTH review report(s) sent to applicant||September 24, 2019|
|Comments from applicant on draft CADTH review report(s) received||October 03, 2019|
|CADTH review team's comments on draft CADTH review report(s) sent to applicant||November 08, 2019|
|Canadian Drug Expert Committee (CDEC) meeting||November 20, 2019|
|CDEC recommendation sent to applicant and drug plans||December 02, 2019|
December 04, 2019